Navigation Links
Johns Hopkins Medicine Acquires Naviscan PEM Technology for Novel Radiotracer Research
Date:2/18/2010

SAN DIEGO, Feb. 18 /PRNewswire/ -- Johns Hopkins Medicine has become the latest academic medical center to acquire the Naviscan Positron Emission Mammography (PEM) scanner.  The device will be utilized by Richard Wahl, M.D., F.A.C.R, Professor of Radiology and Nuclear Medicine at the Johns Hopkins University School of Medicine, in pre-clinical and translational research for the development of novel radiotracers.

"As the use of Naviscan's organ-specific PET imaging technology continues to be used in cutting-edge breast cancer research and clinical patient management, Naviscan is also developing its use in new clinical applications. As a result, the development and clinical validation of novel radiotracers is essential," said Paul J. Mirabella, Chairman and CEO, Naviscan, Inc.  

Dr. Wahl patented the technology which enabled Naviscan to develop the first and only FDA-cleared PET-guided biopsy accessory, known as Stereo Navigator®. Naviscan obtained an exclusive license to this patent, which Wahl developed while he was at the University of Michigan.

Other academic medical centers utilizing Naviscan's PEM technology include University of Cincinnati, Baylor University, M.D. Anderson, University of Chicago, and the Boston University Medical Center.  

About Naviscan, Inc.

Naviscan, founded in 1995, develops and markets compact, high-resolution PET scanners intended to provide organ-specific molecular imaging and guide radiological and surgical procedures. The Naviscan PET scanner is currently installed and available in breast and imaging centers throughout the U.S. and other parts of the world. The Company is headquartered in San Diego, California and is the first to obtain FDA clearance for a high-resolution PET scanner designed to image small body parts and for breast biopsy image guidance.  For more information, call 1.858.587.3641 or visit www.naviscan.com.

SOURCE Naviscan, Inc.

RELATED LINKS
http://www.naviscanpet.com

'/>"/>

SOURCE Naviscan, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. U.S. Files Suit Against Johnson & Johnson For Paying Kickbacks to Nations Largest Nursing Home Pharmacy
2. Emerging Agents from Theravance/Astellas, Johnson & Johnson/Basilea and Forest/Astrazeneca/Takeda Will Drive Modest Growth in the MRSA Drug Market Through 2018
3. EF Johnson Technologies Announces Third Quarter Results
4. Seguro Acquires Worldwide Rights to Johns Hopkins Abdominal Surgery Device
5. Palomar to Commercialize FDA Cleared Over-The-Counter Home Use Wrinkle Treatment Laser Device Without Johnson & Johnson
6. Somanetics Acquires Exclusive Sublicense to Cerebral Autoregulation Monitoring Technology Developed at The Johns Hopkins University
7. Boston Scientific and Johnson & Johnson Announce Settlement of Patent Disputes
8. Johnson & Johnson Announces Support for Kohl-Grassley Physician Payments Sunshine Act of 2009
9. Simbionix and Johnson & Johnson LLC Announce Distribution Agreement at Russia and the CIS Countries
10. Johnson & Johnson Pharmaceutical Research & Development, L.L.C. Announces FDA Filings for Paliperidone Palmitate and INVEGA(R)
11. Johns Hopkins University Researchers to Clinically Assess Rosetta Genomics miRview(TM) Squamous Assay
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/4/2017)... -- Agragen, LLC, a Cincinnati -based ... and aquacultural feed sectors, announces a significant step ... AGR131.  This drug is designed to trap and ... patients suffering from inflammatory conditions such as rheumatoid ... Biological pharmaceuticals currently used ...
(Date:8/2/2017)...   Marshall County Hospital in Benton, Kentucky has added ... hospital-acquired infections (HAIs). The new addition, Tru-D SmartUVC , short for "total room ultraviolet ... such as C. diff , MRSA, MERS, Ebola and more. ... Tru-D SmartUVC ... Tru-D in action in a patient room ...
(Date:8/1/2017)...   CerSci Therapeutics , a non-opioid drug development ... has received notice from the National Institute on Drug ... that it has been awarded a Direct-to-Phase II Small ... 2017 with an additional $1,000,000 to follow in 2018. ... of their lead non-opioid drug candidate CT-044 to the ...
Breaking Medicine Technology:
(Date:8/18/2017)... ... August 18, 2017 , ... ... services to communities in east Texas, is launching a regional charity effort to ... Founded in 1991, the Pediatric Brain Tumor Foundation (PBTF) has raised nearly $30 ...
(Date:8/18/2017)... Bedford, TX (PRWEB) , ... August 18, 2017 , ... ... serves communities in the Dallas/Fort Worth area, is spearheading a regional charity campaign organized ... her husband. , In early June of this year, Christina and her children returned ...
(Date:8/18/2017)... ... 2017 , ... Alcovit, a lime-flavored beverage that rids the body of toxins ... product now available through Jet.com. , After 25 years of development, the company ... designed to quickly detox the body thereby avoiding alcohol-induced hangovers. Whether you’re having fun ...
(Date:8/18/2017)... , ... August 18, 2017 , ... “Dangerous Inheritance”: a ... author, Diane Winters. Diane is from Southwest Nebraska where she was raised on ... and family. The story is fictional, but the friendships and mantra of ‘neighbors ...
(Date:8/18/2017)... ... August 18, 2017 , ... Rollon Skin ... anti-aging skincare solutions, recently announced the launch of two new skincare products, ... yet effective alternative to expensive plastic surgery or in-patient cosmetic dermatological procedures. , ...
Breaking Medicine News(10 mins):